MedTrace Logo

Zinc Supplementation Improves Cardiovascular Morbidity in Patients With Diabetes Mellitus

NCT05000762 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-12-12

No results posted yet for this study

Summary

Oral zinc supplementation in patients with diabetes mellitus can improve glycemic control. However, there is reluctance to recommend zinc supplements to these patients because there is no evidence that the zinc-dependent improvement in glycemic control offers protections from the cardiovascular morbidities associated with diabetes mellitus, especially myocardial infarction and thrombotic stroke. The investigators are conducting a randomized, double blind, cross over study to test the hypothesis that oral zinc supplementation will block the enhanced cardiovascular, cerebrovascular, and platelet reactivity that lead to myocardial infarction and stroke in research participants with diabetes mellitus.

Conditions

Interventions

DIETARY_SUPPLEMENT

Zinc

Zinc gluconate 30 mg/day orally

Sponsors & Collaborators

  • QPathology

    collaborator UNKNOWN

  • Wayne State University

    lead OTHER

Principal Investigators

  • Warren Lockette, MD · Wayne State University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05000762 on ClinicalTrials.gov